Maywufa Co., Ltd. AI Stock Analysis
Maywufa Co., Ltd. (1731) AI Stock Analysis
Maywufa Co., Ltd.
(TWSE:1731)
The score is driven primarily by solid fundamentals: high, stable gross margins, consistent revenue growth, a conservatively leveraged balance sheet and a strong 2025 free cash flow rebound. Valuation adds support, with an undemanding 13.7 P/E and a generous 5.9% dividend yield. These positives are tempered by five years of margin compression that has left net income essentially flat, a modest 8% return on equity, and a neutral-to-soft technical picture, with the price drifting just below all key moving averages and momentum indicators showing mild weakness. The result is a defensive, income-oriented profile with limited near-term catalysts.
Maywufa Co., Ltd. (1731) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.77B
- Dividend Yield
- 5.87%
- Average Volume (3M)
- 99.42K
- Price to Earnings (P/E)
- 13.8
- Beta (1Y)
- 0.13
- Revenue Growth
- 7.65%
- EPS Growth
- 15.75%
- Country
- TW
- Employees
- 282
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
Maywufa Co., Ltd. Business Overview & Revenue Model
Company Description
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. The company engages in the manufacturing, processing, and distribution of hairdressing products, soap, and cosmetics; distribution, wholesale,...
Maywufa Co., Ltd. Financial Statement Overview
Summary
Maywufa combines steady revenue growth (roughly 50% since 2020, +7% in the latest year) with exceptionally durable gross margins above 60%, a conservatively funded balance sheet (two-thirds equity financed, debt-to-equity of 0.30) and strong 2025 cash generation, with operating cash flow of NT$228 million covering net income 1.26 times and free cash flow rebounding to a positive NT$211 million. Offsetting these strengths are persistent margin erosion (operating margin down from 20% to 13.7%, net margin from 16.1% to 11.4%), flat net income despite strong sales growth, a modest 8.4% return on equity, rising borrowings off a low base, and lumpy capital spending that has made free cash flow volatile.
Income Statement
68PositiveBalance Sheet
74PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.64B | 1.58B | 1.49B | 1.30B | 1.25B | 1.29B |
| Gross Profit | 997.29M | 1.00B | 961.75M | 854.37M | 816.56M | 859.44M |
| EBITDA | 258.44M | 271.75M | 258.65M | 239.13M | 239.54M | 248.12M |
| Net Income | 201.32M | 181.00M | 173.23M | 169.10M | 161.83M | 164.32M |
Balance Sheet | ||||||
| Total Assets | 3.48B | 3.24B | 3.18B | 2.83B | 2.53B | 2.69B |
| Cash, Cash Equivalents and Short-Term Investments | 755.38M | 620.06M | 605.49M | 573.61M | 584.38M | 879.67M |
| Total Debt | 640.73M | 641.77M | 673.80M | 442.67M | 227.00M | 317.16M |
| Total Liabilities | 1.29B | 1.07B | 1.07B | 794.91M | 532.92M | 686.54M |
| Stockholders Equity | 2.19B | 2.16B | 2.11B | 2.04B | 2.00B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 330.26M | 210.60M | -58.09M | -9.81M | -82.51M | 257.36M |
| Operating Cash Flow | 343.95M | 227.85M | 215.69M | 244.32M | 147.88M | 262.98M |
| Investing Cash Flow | -7.90M | 5.20M | -283.93M | -308.39M | 36.20M | -210.95M |
| Financing Cash Flow | -161.65M | -196.48M | 62.35M | 66.52M | -245.54M | -140.29M |
Maywufa Co., Ltd. Peers Comparison
Overall Rating
TW:178071Outperform- TW:173167Neutral
TW:175265.4Neutral
TW:173363Neutral
TW:843352Neutral
TW:650441Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1780 | 71Outperform | TWD 2.59B | 8.03 | ― | 5.27% | ― | ― |
| TW:1731 | 67Neutral | TWD 2.77B | 13.77 | ― | 5.87% | 7.65% | 15.75% |
| TW:1752 | 65Neutral | TWD 3.02B | 16.07 | ― | 5.35% | -6.10% | -26.89% |
| TW:1733 | 63Neutral | TWD 2.85B | 15.05 | ― | 4.55% | -5.22% | 22.94% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:8433 | 52Neutral | TWD 2.68B | 7.66 | ― | 8.55% | 9.23% | 66.23% |
| TW:6504 | 41Neutral | TWD 2.58B | -547.06 | ― | 2.69% | -1.43% | 92.88% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1731 | Maywufa Co., Ltd. | 20.80 | -0.02 | -0.08% | |
| TW:1733 | Apex Biotechnology Corp. | 28.60 | -1.34 | -4.47% | |
| TW:1752 | Nang Kuang Pharmaceutical Co., Ltd. | 29.90 | -6.84 | -18.62% | |
| TW:1780 | Allied Biotech Corp | 23.70 | 6.00 | 33.88% | |
| TW:6504 | Nan Liu Enterprise Co., Ltd | 37.20 | -4.91 | -11.66% | |
| TW:8433 | Bon Fame Co., Ltd. | 49.15 | -0.50 | -1.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026